ARS PHARMACEUTICALS INC (SPRY) competitors & alternatives
Health Care · NASDAQ
ARS PHARMACEUTICALS INC (SPRY)'s top competitors and alternatives — its most similar public companies — include AQUESTIVE THERAPEUTICS INC (AQST), AMPHASTAR PHARMACEUTICALS INC (AMPH), KORU MEDICAL SYSTEMS INC (KRMD), Universal Health Services (UHS), PACIRA BIOSCIENCES INC (PCRX), OCULAR THERAPEUTIX INC (OCUL), Bristol Myers Squibb (BMY), Tenet Healthcare (THC), ALTO NEUROSCIENCE INC (ANRO), INVIVYD INC (IVVD), VERADERMICS INC (MANE) and RELMADA THERAPEUTICS INC (RLMD). These are ARS PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SPRY competitors & alternatives
-
AQUESTIVE THERAPEUTICS INCAQSTHealth Care
Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film…
$3.94 (as of 2026-07-22) · market cap $496M
-
AMPHASTAR PHARMACEUTICALS INCAMPHHealth Care
Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging…
$19.30 (as of 2026-07-22) · market cap $864M
-
KORU MEDICAL SYSTEMS INCKRMDHealth Care
Koru Medical manufactures FREEDOM Infusion Systems for at-home subcutaneous drug delivery, primarily for immunoglobulin therapy in immunodeficiency diseases,…
$3.86 (as of 2026-07-22) · market cap $177M
-
Universal Health ServicesUHSHealth Care
Large diversified hospital operator running 375 acute care and behavioral health inpatient facilities across the US, UK, and Puerto Rico, with 42% of revenues…
$149.34 (as of 2026-07-22) · market cap $9.1B
-
PACIRA BIOSCIENCES INCPCRXHealth Care
Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis…
$25.59 (as of 2026-07-22) · market cap $1.0B
-
OCULAR THERAPEUTIX INCOCULHealth Care
Ocular Therapeutix is a biopharmaceutical company leveraging proprietary bioresorbable hydrogel technology to deliver retinal therapies, with AXPAXLI…
$8.59 (as of 2026-07-22) · market cap $2.0B
-
Bristol Myers SquibbBMYHealth Care
Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse…
$60.76 (as of 2026-07-22) · market cap $124.9B
-
Tenet HealthcareTHCHealth Care
A nationwide hospital and ambulatory surgery network with deep expertise in acute, specialty, and emergency care, backed by value-based care and revenue cycle…
$195.35 (as of 2026-07-22) · market cap $16.9B
-
ALTO NEUROSCIENCE INCANROHealth Care
Alto Neuroscience is a clinical-stage biotech developing precision medicines for neuropsychiatric conditions by using biomarkers to match patients to targeted…
$27.23 (as of 2026-07-22) · market cap $1.0B
-
INVIVYD INCIVVDHealth Care
Invivyd develops monoclonal antibody therapeutics for serious viral infections, with PEMGARDA approved for COVID-19 emergency use and a pipeline targeting RSV,…
$0.62 (as of 2026-07-22) · market cap $183M
-
VERADERMICS INCMANEHealth Care
VeraDermics is a clinical-stage biotech developing an oral, extended-release minoxidil formulation (VDPHL01) to address the 80 million Americans with pattern…
$109.85 (as of 2026-07-22) · market cap $4.5B
-
RELMADA THERAPEUTICS INCRLMDHealth Care
Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead…
$5.00 (as of 2026-07-22) · market cap $524M
Not quite? Describe exactly what you want →
Peers are ARS PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ARS PHARMACEUTICALS INC (SPRY).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.